Document is current

Article History

Received: 27 June 2023

Accepted: 9 November 2023

First Online: 27 November 2023

Declarations

:

: This study was approved by the medical ethics review committee of the VU University Medical Center (reference number 2012/302). All participants provided written informed consent to participate in the study. The study was conducted following the Protocol and the Declaration of Helsinki and Good Clinical Practice.

: N/a.

: Lyduine E. Collij has received research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly). Both are paid to the institution.Gill Farrar is a full-time employee of GE Healthcare.Marissa Zwan reports no relevant disclosures.Elsmarieke van Giessen reports no relevant disclosures.Rik Ossenkoppele has received a speakers fee from GE Healthcare (paid to the institution) and receives research support from Avid Radiopharmaceuticals. RO is an editorial board member for the European Journal of Nuclear Medicine and Molecular Imaging and for Alzheimer’s Research & Therapy.Frederik Barkhof received payment and honoraria from Bayer Genzyme, Biogen-Idec, TEVA, Merck, Novartis, Roche, IXICO Ltd, GeNeuro, and Apitope Ltd for consulting; payment from the IXICOLtd, and MedScape for educational presentations; research support via grants from EU/EFPIA Innovative Medicines Initiative Joint Undertaking (AMYPAD consortium), EuroPOND (H2020), UK MS Society, Dutch MS Society, PICTURE (IMDI-NWO), NIHR UCLH Biomedical Research Centre (BRC), ECTRIMS-MAGNIMS.Annemieke Rozemuller reports no relevant disclosures.Yolande Pijnenburg reports no relevant disclosures.Wiesje M. van der Flier Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Biogen MA Inc, Boehringer Ingelheim, Life-MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF has performed contract research for Biogen MA Inc., and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. WF is a consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc and Roche. All funding is paid to her institution. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is an associate editor at Brain.Femke Bouwman has research projects in cooperation with Optina Dx and Optos who paid to her institution Alzheimer Center, VU University Medical Center. She has received speaker’s fees paid to the institution from Roche and Biogen.